Exchange Traded Concepts LLC Sells 34,648 Shares of Dynavax Technologies Corporation (NASDAQ:DVAX)

Exchange Traded Concepts LLC cut its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 21.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 128,078 shares of the biopharmaceutical company's stock after selling 34,648 shares during the quarter. Exchange Traded Concepts LLC owned 0.10% of Dynavax Technologies worth $1,661,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at $35,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at $71,000. Finally, GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 88.4% during the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 3.1%

NASDAQ DVAX traded up $0.31 during trading on Wednesday, reaching $10.30. 3,059,180 shares of the company's stock were exchanged, compared to its average volume of 2,201,443. Dynavax Technologies Corporation has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The company's fifty day simple moving average is $10.37 and its 200-day simple moving average is $12.12. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $1.24 billion, a PE ratio of -19.81 and a beta of 1.06.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The company had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million. Sell-side analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DVAX shares. Wall Street Zen lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. JMP Securities decreased their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group decreased their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Dynavax Technologies has a consensus rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.